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Forging a potent vaccine adjuvant:
CpG ODN/cationic peptide nanorings
Bilgi Gungor1, Fuat Cem Yagci2, Ihsan Gursel2, and Mayda Gursel1,*
1Department of Biological Sciences; Middle East Technical University; Ankara, Turkey; 2Department of Molecular Biology and Genetics Bilkent University; Ankara, Turkey
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Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or
alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to
convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon a (IFNa) stimulating activity into a robust Type I
interferon inducer with potent vaccine adjuvant activity.
Single stranded synthetic oligodeoxy-
nucleotides containing unmethylated
cytosine-phosphate-guanine dinucleotide
motifs (CpG ODN) mimic the immune
stimulatory effect of bacterial DNA and
constitute a family of immunotherapeutics
that stimulate the cells of the innate
immune system expressing the endosomal
pattern recognition receptor Toll-like
receptor 9 (TLR9).1 CpG ODNs are clas-
sified into 4 distinct subtypes on the basis
of their sequence, the nature of the ODN
backbone, the presence of secondary struc-
tures and differential immune activation
patterns observed among stimulated
human peripheral blood mononuclear
cells (PBMCs).2 Of these, K-class CpG
ODNs (referred to as CpG-B by other
groups) have linear phosphorothioate (PS)
backbones, express multiple TCGTT
and/or TCGTA motifs and strongly acti-
vate B cells.3 K-ODNs promote the sur-
vival, activation and maturation of
plasmacytoid dendritic cells (pDC) but
induce no IFNa secretion.3-5 To date, the
majority of clinical trials have been based
on this ODN class.6 The D-class ODN
(referred to as CpG-A by other groups),
contain a single palindromic phospho-
diester purine/pyrimidine/CG/purine/
pyrimidine motif linked to a poly(G) tail
at their 3’ end.3 The palindromic
sequence and the poly(G) tail enable D
type ODNs to form Hoogsteen base
paired G-quadruplexes and higher order
structures that can be globular (»50 nm
size), linear (»100 nm size) or 2 forked.7
Formation of such multimeric structures
permits D- but not K-type ODN to bind
to the transmembrane form of the chemo-
kine and scavenger receptor chemokine
(C-X-C) ligand 16 (CXCL16) expressed
on the surface of pDCs.8 This interaction
directs the ODN into early endosomes,
triggering a TLR9-MyD88-IRF7-medi-
ated signaling pathway, leading to robust
IFNa production.9 The D-ODN-induced
vigorous IFNa response may have poten-
tial benefits in the prevention/treatment
of viral infections and/or malignancies.
However, formation of spontaneous,
uncontrollable higher order structures
with D-class ODN complicates their
pharmaceutical manufacturing process,
precluding them from human clinical tri-
als. The remaining 2 CpG ODN classes
are either weak Type I interferon-inducers
(C-class), or are dependent upon “high-
salt buffers” to form IFNa stimulating
concatameric structures (P-class), making
them less potent or unpredictable for use
as alternates of D-ODN.
Recently, we have demonstrated a
simple strategy to convert a conventional
K-type ODN into a potent Type I inter-
feron inducer by multimerizing the ODN
into ordered nanostructures through com-
plexation with a cationic peptide.10 In
general, polycation induced condensation
of ODN generates aggregates with a het-
erogeneous distribution. To avoid such an
outcome, we hypothesized that a very
short and hence non-flexible ODN would
condense into well-defined spheres when
mixed with a short peptide of high posi-
tive charge density. Our results demon-
strated that among the cationic peptides
tested, the 11-mer, C8 charged HIV-
derived peptide Tat(47–57) condensed a
12-mer but not a more flexible 20-mer
ODN into rigid individual building
blocks that subsequently re-organized to
forge stable, monodispersed nanorings
(Fig. 1A).10 The nanorings generated a
vigorous pDC-dependent IFNa response
and an indirect monocyte-dependent
CXCL10/IP-10 response in human
blood that reciprocated D-ODN activ-
ity.10 Since differences in subcellular dis-
tribution of ODN directly affect the
type of response (i.e, the IFNa eliciting
capacity), we further analyzed the endo-
somal localization patterns. Results
showed that condensation with Tat pep-
tide redirected K-ODN to early endo-
somes (Fig. 1A). This subcellular
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distribution pattern is consistent with
efficient IFNa production.
The nanorings were also found to be
more effective than K-ODN in
stimulating long-term antigen-specific
antibody production in vivo when ad-
mixed with a suboptimal dose of the
inactivated foot and mouse disease
vaccine.10 The response was
characterized by an isotype
switching toward IgG2a, sug-
gestive of T helper type 1
(Th1) support (Fig. 1B). In a
different setting, C57BL/6
mice bearing ovalbumin
(OVA)-expressing EG.7 thy-
moma tumors were therapeuti-
cally vaccinated with the model
tumor antigen OVA plus the
adjuvants. The nanoring adju-
vanted group displayed signifi-
cant reduction in tumor size
and progression.10 Type I
interferons can directly trigger
clonal expansion and memory
formation in CD8C T cells.
Consistent with this view,
nanorings triggered expansion
in the CD8C T cell pool and
elicited superior tumor-specific
immunity (Fig. 1B) character-
ized by increased OVA-specific
interferon g (IFNg) produc-
tion. Next, to assess whether
the nanorings required the
presence of pDCs for their
activity, we depleted this cell
population in vivo and exam-
ined the induction of antibody
response to the model antigen
OVA. In pDC undepleted
mice, both the nanoring and
the D-ODN adjuvanted
groups generated approxi-
mately 80-fold higher OVA-
specific IgG2a titers when
compared to antigen alone.
This activity was severely
impaired in mice depleted of
pDCs, suggesting that pDC
activation and ensuing Type I
IFN production is critical for
the adjuvanticity.10
Clinical use of Type I inter-
feron-inducing TLR agonists
such as the TLR7/8 agonist
R837 is currently limited to the
topical treatment of genital
warts, basal cell carcinoma, and
bladder cancer. Systemic
administration of imidazoquinolines
incite a TLR7-independent immunotoxic-
ity by antagonizing the adenosine recep-
tors. Therefore, the development of other
Figure 1. Assembly and mechanism of action of CpG ODN/Tat nanorings. (A). The cationic peptide con-
denses K-type CpG ODN into rigid individual building blocks that re-organize to form nanoring structures.
Nanorings are internalized by pDC and translocate to early endosomes where they initiate a TLR9-MyD88-IRF7-
mediated signaling pathway, leading to IFNa production. In free form, K-ODN localize to late endosomes, and
are not qualiﬁed to trigger an interferon response. (B). Nanoring-stimulated pDCs secrete Type I interferons,
supporting antigen-speciﬁc humoral and cellular immunity in vivo. Ag, antigen; CpG ODN, cytosine-guanine oli-
godeoxynucleotides; IFNa, interferon a; IFNg, interferon g; pDC, plasmacytoid dendritic cells; Tat, 8 residue
charged HIV-derived peptide Tat(47–57); Th1, T helper type 1; TLR9, Toll-like receptor 9.
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TLR-based Type I interferon inducers
suitable for systemic use as adjuvants is
highly desirable. We believe that our
recent findings in regards to the perfor-
mance of the nanorings in vivo are encour-
aging and may prove to be of value as
antiviral or anticancer agents and vaccine
adjuvants in the clinic. However, whether
the nanorings would withstand testing in
non-human primates where the cellular
expression of TLR9 is more restricted
than in mice remains to be seen.
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